Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Niels E Wondergem und 19 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, De Boelelaan 1117, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Mouth Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Background
Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome.
Methods
In this study, 16 evaluable patients with stage III/IV oral cancer were treated with one dose of 480 mg nivolumab 3 weeks prior to surgery. Primary objectives were safety, feasibility, and suitability of programmed death receptor ligand-1 positron emission tomography (PD-L1 PET) as a biomarker for response. Imaging included 18 F-BMS-986192 (PD-L1) PET and 18 F-fluorodeoxyglucose (FDG) PET before and after nivolumab treatment. Secondary objectives included clinical and pathological response, and immune profiling of peripheral blood mononuclear cells (PBMCs) for response prediction. Baseline tumor biopsies and postnivolumab resection specimens were evaluated by histopathology.
Results
Grade III or higher adverse events were not observed and treatment was not delayed in relation to nivolumab administration and other study procedures. Six patients (38%) had a pathological response, of whom three (19%) had a major (≥90%) pathological response (MPR). Tumor PD-L1 PET uptake (quantified using standard uptake value) was not statistically different in patients with or without MPR (median 5.3 vs 3.4). All major responders showed a significantly postnivolumab decreased signal on FDG PET. PBMC immune phenotyping showed higher levels of CD8 + T cell activation in MPR patients, evidenced by higher baseline expression levels of PD-1, TIGIT, IFNγ and lower levels of PD-L1.
Conclusion
Together these data support that neoadjuvant treatment of advanced-stage oral cancers with nivolumab was safe and induced an MPR in a promising 19% of patients. Response was associated with decreased FDG PET uptake as well as activation status of peripheral T cell populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC location Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, De Boelelaan 1117, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
- Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Cancer Centre Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, Netherlands.
- Amsterdam UMC location Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.
ORCID-Profile: Niels E Wondergem, Iris H C Miedema, Rieneke van de Ven, Gerben J C Zwezerijnen, Pim de Graaf, K Hakki Karagozoglu, Jan-Jaap Hendrickx, Simone E J Eerenstein, Jens Voortman, Ronald Boellaard, Albert D Windhorst, Laura A N Peferoen, Tanja D de Gruijl, Elisabeth Bloemena, Ruud H Brakenhoff, C René Leemans, C Willemien Menke-van der Houven van Oordt
Förderung
- Bristol Myers Squibb
Zitieren
APA
Wondergem, N. E., Miedema, I. H. C., van de Ven, R., Zwezerijnen, G. J. C., de Graaf, P., Karagozoglu, K. H., Hendrickx, J. J., Eerenstein, S. E. J., Bun, R. J., Mulder, D. C., Voortman, J., Boellaard, R., Windhorst, A. D., Hagers, J. P., Peferoen, L. A. N., de Gruijl, T. D., Bloemena, E., Brakenhoff, R. H., Leemans, C. R., & Menke-van der Houven van Oordt, C. W. (2024). Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009278
Vancouver
Wondergem NE, Miedema IHC, van de Ven R, Zwezerijnen GJC, de Graaf P, Karagozoglu KH, et al. Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009278
BibTeX
@article{Wondergem2024,
author = {Wondergem, Niels E and Miedema, Iris H C and van de Ven, Rieneke and Zwezerijnen, Gerben J C and de Graaf, Pim and Karagozoglu, K Hakki and Hendrickx, Jan-Jaap and Eerenstein, Simone E J and Bun, Rolf J and Mulder, Dorien C and Voortman, Jens and Boellaard, Ronald and Windhorst, Albert D and Hagers, J Pascal and Peferoen, Laura A N and de Gruijl, Tanja D and Bloemena, Elisabeth and Brakenhoff, Ruud H and Leemans, C René and Menke-van der Houven van Oordt, C Willemien},
title = {Circulating T cell status and molecular imaging may predict clinical benefit of neoadjuvant PD-1 blockade in oral cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009278}
}
EUVIMED